Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01315093

Enrollment

Registered

2011-03-15

Start date

2010-11-30

Completion date

2016-06-30

Last updated

2018-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

In Vitro Fertilisation, poor responders

Brief summary

The addition of heparin increases pregnancy outcome parameters in poor responders undergoing In Vitro Fertilisation (IVF)

Interventions

DRUGHeparin, Low-Molecular-Weight

Heparin from start till hcg test

DRUGno heparin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 43 Years

Healthy volunteers

Yes

Inclusion criteria

* poor responders (age\>40, abnormal ovarian test, \</=4 oocytes in previous cycle with conventional stimulation) * infertility, indication for IVF * no contraindications for heparin

Design outcomes

Primary

Measure	Time frame	Description
no of oocytes retrieved	egg recovery, 2 years	\>2 between groups

Secondary

Measure	Time frame	Description
clinical pregnancy rate	2 years	Presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks
live birth rate	2 years	\>20 weeks of gestation
cancellation rate	before ET, 2 years	—
miscarriage rate	2 years	pregnancy loss \<20 weeks

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026